LinkedIn · May 2026
Announces EditABLE, an open-source CRISPR experiment-design tool, and says the work supports Nephrogen’s kidney-disease therapeutic pipeline.
Curative gene therapies for kidney diseases
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Stanford-origin biotech spinout developing NeFIND, an AI and high-throughput in vivo screening platform for kidney- and pancreas-targeted gene delivery; the company’s lead focus is curative genetic medicines for PKD and other hard-to-deliver renal/pancreatic diseases.
Primary product
NeFIND AI screening platform for kidney/pancreas-targeted AAV and gene-delivery vehicle discovery
Founded
2022
Headquarters
New York, New York, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Gene therapy / genetic medicine
Offices
1361 Amsterdam Ave, Suite 320, New York, NY 10027
Biolabs @ NYU Langone, 45-18 Court Square, Floor 6, Long Island City, NY 11101
700 Main St, Cambridge, Massachusetts 02139
100 Cummings Ctr Ste 451C, Beverly, Massachusetts 01915, United States
Business model
platform biotechnology
preclinical therapeutic development
research collaborations
Funding
Stage
seed-stage
Total raised
$2.3M
Latest round
Pre-Seed · Nov 2025
Latest amount
$2M
Nov 2025 · ZAKA VC
Sep 2023 · HHS/NIH
People & investors
Leadership
Co-Founder and CEO
Co-Founder and Chief Medical Advisor
Chang Hong, JD
Chief Business Officer
Miriam Rivera Moreno
Research Associate
Andrea An
Research Associate
Co-Founder
Avnesh Thakor, MD, PhD
Scientific Advisor
Mark Kay, MD, PhD
Scientific Advisor
Terry Watnick, MD
Scientific Advisor
Vishal Patel, MD
Scientific Advisor
Jan Liphardt, PhD
Scientific Advisor
Work & culture
Mission-driven, research-heavy, translational startup culture; public signals emphasize publications, conference presentations, and advancing kidney gene-therapy science rather than perks.
Compensation
A public Research Associate posting listed $55,000-$70,000/year, onsite in New York, with no stock options mentioned.
Product & market
Differentiators
- —Kidney- and pancreas-specific gene-delivery focus
- —AI plus high-throughput in vivo screening
- —Reported 10-100x more efficient AAV delivery vehicles
- —Strong Stanford/academic origin
- —Public preclinical dataset and open scientific publication cadence
Technology
AI
high-throughput in vivo screening
AAV delivery vehicles
CRISPR-Cas editing
Webflow
Competitors
Capsida
Dyno
4D Molecular Therapeutics
Scale & contact
Latest news
ITKeyMedia · Nov 2025
Reports a closed $2M pre-seed led by ZAKA VC, describes NeFIND, and says the company expects clinical trials in 2027.
TechCrunch · Oct 2025
Profiles Nephrogen’s 2022 founding, kidney-focused gene-delivery platform, 100x efficiency claim, and plans to begin clinical studies in 2027 while raising a $4M seed round.
LinkedIn · Oct 2025
Demetri Maxim shared a new pre-print on AAV vectors for kidney gene therapy, with collaborators from Stanford, Harvard Medical School, and Revalia Bio.
LinkedIn · May 2025
Company announced its first public data presentation at ASGCT 2025 and highlighted preclinical kidney gene-delivery data and its PKD lead program.
Jobs and careers at Nephrogen
0 jobs at Nephrogen
No open positions
Check back later for new openings